We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities... BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. Show more
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company developing innovative...
FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company developing innovative...
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC...
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (βBeyondSpringβ or the βCompanyβ), a clinical-stage global biopharmaceutical company focused on developing...
The SEED-Eisai Research Collaboration leverages Eisaiβs leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.14 | -7.60869565217 | 1.84 | 2.28 | 1.615 | 22889 | 1.82094859 | CS |
4 | -0.45 | -20.9302325581 | 2.15 | 2.28 | 1.5016 | 27254 | 1.79972633 | CS |
12 | -0.35 | -17.0731707317 | 2.05 | 2.6 | 1.5016 | 25410 | 2.0960574 | CS |
26 | -0.94 | -35.6060606061 | 2.64 | 2.974 | 1.5016 | 32748 | 2.25381072 | CS |
52 | 0.8119 | 91.4198851481 | 0.8881 | 4 | 0.7777 | 83624 | 2.51659121 | CS |
156 | -2.56 | -60.0938967136 | 4.26 | 5.175 | 0.542 | 283775 | 2.60645482 | CS |
260 | -11.3 | -86.9230769231 | 13 | 33 | 0.542 | 456654 | 13.16250087 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions